Bliss GVS Pharma Seeks Shareholder Approval for New Board Appointments

Bliss GVS Pharma Ltd has officially commenced a postal ballot process to secure shareholder approval for the appointment of three new directors to its board. The resolution follows the company’s recent change in promoter control, involving Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited.

Reader Takeaway: New leadership follows promoter change, marking a shift in corporate governance as the board aligns with new ownership.

What just happened

The company has proposed the appointment of Mr. Hetul Krishnakant Mehta, Mr. Amar Dilip Shah, and Mr. Pramod Badrinarayan Kasat as Non-Executive Non-Independent Directors. These individuals were appointed as additional directors effective September 28, 2026, pending final approval through this postal ballot.

Why this matters

The appointment of these directors is a strategic step for the company to reconstitute its board under the guidance of its new promoters. The change reflects the transition initiated after the completion of the Share Purchase Agreement (SPA) dated May 23, 2026, and the subsequent open offer, which finalized the change in control.

Voting Process and Timeline

The voting process is conducted exclusively through remote e-voting, and eligible shareholders must be registered by the cut-off date of October 9, 2026.

• Voting Start: October 16, 2026, at 9:00 a.m. IST
• Voting End: November 14, 2026, at 5:00 p.m. IST
• Results Announcement: Expected on or before November 17, 2026

Shareholders may cast their votes using the e-voting facility provided by CDSL. The results will determine the formal induction of the proposed directors to the board, reinforcing the governance structure under the new management regime.